BOSTON SCIENTIFIC CORP

BOSTON SCIENTIFIC CORP (BSX) — Investment Memo

🐂 The Bull Case (Warren's voice)

• Why the moat is durable: Surgeons don’t switch devices once trained. A new catheter or stent means retraining, lost OR time, and malpractice risk. BSX has 50,000 reps embedding their tools into every cath lab and endoscopy suite in the world. That’s a 10‑year switching cost lock.
• What makes the economics exceptional – on the surface:
  • Revenue: $9.1B (2016) → $20.1B (2025) – 9% CAGR, consistently.
  • Free cash flow: $0.8B → $3.7B – 26% CAGR over that period, with a recent surge from $1.8B (2023).
  • Low debt-to-equity (0.16x) suggests balance sheet is not overleveraged.
• At what price does this become attractive? If the DCF is correct ($88.31/share), and if hidden margins are stable, then a 20–30% discount (i.e., $62–$71) offers a proper margin of safety. But we cannot confirm the DCF’s growth assumptions without segment data. The bull case only works if you trust management’s silence. I don’t.

🐻 The Bear Case (Charlie inverts)

Munger’s rule: “Show me where I’ll die and I won’t go there.”

• Scenario 1: Technology disruption (10–15 years)
  • Non‑invasive therapies – oral drugs, AI‑guided robotic ablation, or liquid‑biopsy‑targeted treatments – could replace catheter‑based procedures. BSX’s entire disposable‑tool model becomes obsolete. Surgeons’ switching costs mean nothing if there are no catheters to switch.
• Scenario 2: Empire‑building implosion (5–10 years)
  • 2018 FCF = $0 during revenue growth – an acquisition binge that destroyed cash. Since 2023: Bolt, SoniVie, Cortex, Anrei, Intera, Axonics, Silk Road. No disclosed ROIC on any deal. If one large acquisition fails (e.g., Axonics at $3.8B), goodwill write‑downs will crater earnings and reveal hidden leverage. The €1.5B new bonds in 2025 hint at rising debt.
• Scenario 3: The black box unravels (immediate)
  • Net income, gross margins, ROE, share count – all systematically omitted from the 10‑K. This is not a minor omission; it’s a deliberate fog. If margins are compressing (unknown), the current FCF surge is from cost‑cutting or one‑time items, not moat strength. The 29% EPS CAGR vs 9% revenue CAGR implies massive buybacks – at unstated prices – which could have destroyed value.
• Most likely threat: Scenario 2 – empire‑building. The track record (2018 cash drain, serial deals) is a repeatable pattern. Timeframe: 5 years. The hidden numbers will surface when a deal sours and earnings miss.

💰 Valuation & Margin of Safety

• DCF estimate given: $131.0B total / $88.31 per share (15% FCF growth, 10% discount, 3% terminal). But this DCF is built on sand – FCF growth assumptions are heroic when you can’t see margins or capital intensity.
• Intrinsic value estimate: $70 per share – haircut for missing transparency, acquisition risk, and unknown ROIC. This is a guestimate, not a calculation.
• 25% margin of safety entry: $52.50 (conservative – requires a $70 intrinsic)
• 50% margin of safety entry: $35 (Buffett’s ideal – only if you are certain the moat is real; we are not)
• Current value vs. DCF: The DCF of $88.31 likely overprices the business. Without segment margins, ROE, or honest management, BSX is expensive relative to the information available.

Verdict: PASS

The hidden scorecard (missing net income, margins, ROE, share count) is a deal‑breaker – no amount of revenue growth justifies trusting a black box. At $88 per share, you are paying for transparency you will never get, and the empire‑building acquisition history guarantees a future write‑off. Pass until management opens the books.